Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.

Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M, Hajek R, Touzeau C, Boccadoro M, Sonneveld P.

Open source

DOI: 10.1016/s1470-2045(23)00159-6
Published: 2023-06-01
Container: Lancet Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-23-00159-6,
  title = {Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.},
  author = {Ludwig H and  Terpos E and  van de Donk N and  Mateos MV and  Moreau P and  Dimopoulos MA and  Delforge M and  Rodriguez-Otero P and  San-Miguel J and  Yong K and  Gay F and  Einsele H and  Mina R and  Caers J and  Driessen C and  Musto P and  Zweegman S and  Engelhardt M and  Cook G and  Weisel K and  Broijl A and  Beksac M and  Bila J and  Schjesvold F and  Cavo M and  Hajek R and  Touzeau C and  Boccadoro M and  Sonneveld P.},
  year = {2023},
  journal = {Lancet Oncol},
  doi = {10.1016/s1470-2045(23)00159-6},
  url = {https://doi.org/10.1016/s1470-2045(23)00159-6}
}

RIS

TY  - JOUR
TI  - Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
AU  - Ludwig H
AU  -  Terpos E
AU  -  van de Donk N
AU  -  Mateos MV
AU  -  Moreau P
AU  -  Dimopoulos MA
AU  -  Delforge M
AU  -  Rodriguez-Otero P
AU  -  San-Miguel J
AU  -  Yong K
AU  -  Gay F
AU  -  Einsele H
AU  -  Mina R
AU  -  Caers J
AU  -  Driessen C
AU  -  Musto P
AU  -  Zweegman S
AU  -  Engelhardt M
AU  -  Cook G
AU  -  Weisel K
AU  -  Broijl A
AU  -  Beksac M
AU  -  Bila J
AU  -  Schjesvold F
AU  -  Cavo M
AU  -  Hajek R
AU  -  Touzeau C
AU  -  Boccadoro M
AU  -  Sonneveld P.
PY  - 2023
JO  - Lancet Oncol
DO  - 10.1016/s1470-2045(23)00159-6
UR  - https://doi.org/10.1016/s1470-2045(23)00159-6
ER  -

APA

H, L., E, T., N, V. D. D., MV, M., P, M., MA, D., M, D., P, R., J, S., K, Y., F, G., H, E., R, M., J, C., C, D., P, M., S, Z., M, E., G, C., K, W., A, B., M, B., J, B., F, S., M, C., R, H., C, T., M, B., & P., S. (2023). Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.. Lancet Oncol. https://doi.org/10.1016/s1470-2045(23)00159-6

Source records

europe-pmc · retrieved 2026-09-25T21:20:39.398Z